Welcome to our dedicated page for Lemaitre Vasculr news (Ticker: LMAT), a resource for investors and traders seeking the latest updates and insights on Lemaitre Vasculr stock.
LeMaitre Vascular, Inc. provides devices, implants, and services for the treatment of peripheral vascular disease. The company develops, manufactures, and markets disposable and implantable vascular devices for vascular surgeons, with products used in arteries and veins.
Recurring LMAT news includes quarterly financial results, guidance, dividend declarations, and management presentations at healthcare investor conferences. Company updates also discuss product categories such as Artegraft, grafts, valvulotomes, and carotid shunts, along with sales activity across the Americas, EMEA, and Asia Pacific.
LeMaitre Vascular (Nasdaq: LMAT) will present at the Bank of America Healthcare Conference on Wednesday, May 13, 2026 at 5:15 PM PT. Management presentation details and timing are provided for investors and analysts ahead of the event.
LeMaitre Vascular (Nasdaq: LMAT) reported Q1 2026 results: sales $66.6M (+11%, +10% organic), gross margin 72.7% (+350 bps), operating income $17.8M (+41%), and EPS $0.68 (+42%). Cash balance rose to $367.2M. Company declared a $0.25 quarterly dividend and authorized a $100M share repurchase program. Full‑year guidance midpoint: $280M sales, gross margin ~72.3%, and adjusted EPS midpoint $3.00.
LeMaitre Vascular (Nasdaq:LMAT) will release first quarter 2026 financial results on Tuesday, May 5, 2026 after the market close and will host a conference call at 5:00 PM EDT the same day. Access is by registration for dial-in and PIN; an audio webcast and replay will be available at the company investor site.
LeMaitre Vascular (Nasdaq:LMAT) said management will present at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16, 2025 at 2:15 PM EDT.
The virtual presentation provides a scheduled, public management update to investors and analysts; no financial results or additional agenda details were disclosed.
LeMaitre Vascular (Nasdaq:LMAT) said management will participate in five investor conferences in March 2026, including presentations and 1x1 meetings.
Events:
- Leerink Partners Global Healthcare Conference — Mar 10, 2026, W South Beach, Miami, presentation 1:00 PM EDT
- Citizens Life Sciences Conference — Mar 11, 2026, Eden Roc Miami Beach, presentation 1:40 PM EDT
- Barclays Annual Global Healthcare Conference — Mar 12, 2026, available for 1x1 meetings
- KeyBanc Capital Markets Healthcare Forum — Mar 17, 2026, virtual, presentation 3:45 PM EDT
- 38th Annual ROTH Conference — Mar 22-24, 2026, available for 1x1 meetings and possible presentation
LeMaitre Vascular (Nasdaq: LMAT) reported Q4 2025 results with $64.5mm sales (+16%, +15% organic), gross margin 71.7% (+240 bps), operating income $18.8mm (+47%) and diluted EPS $0.68 (+39%). Cash rose to $359.1mm. The board approved a 25% dividend increase to $0.25/share and a $100mm repurchase authorization. Management guided FY2026 sales to a $276–$284mm range (mid $280mm, +12%) and mid op income of $77.8mm (adj. +21%).
Q4 growth was broad-based with grafts, valvulotomes and carotid shunts up and international strength in EMEA and APAC. Q1 2026 mid-sales guidance is $66.6mm (+11%).
LeMaitre Vascular (Nasdaq:LMAT) will release fourth-quarter 2025 financial results on February 25, 2026 after the market close. A conference call is scheduled the same day at 5:00 PM EST to review results, business highlights, and company outlook. The live audio webcast and replay will be available at the company investor website, and registrants receive dial-in details and a PIN.
LeMaitre Vascular (Nasdaq:LMAT) announced management will participate in three investor conferences in Nov–Dec 2025.
- Jefferies London Healthcare Conference — Tuesday, November 18, 2025 at 8:00 AM GMT at Waldorf Hilton, London; presenter: Dorian LeBlanc, CFO.
- Wolfe Research 7th Annual Healthcare Conference — Wednesday, November 19, 2025 at 10:40 AM ET at Wolfe NYC Offices, New York; presenter: David Roberts, President.
- Piper Sandler 37th Annual Healthcare Conference — Thursday, December 4, 2025 at 3:20 PM ET at Lotte Palace, New York; presenter: Dorian LeBlanc, CFO.
LeMaitre Vascular (Nasdaq: LMAT) reported Q3 2025 results and raised guidance on Nov. 6, 2025. Q3 sales were $61.0mm (+11% overall, +12% organic). GAAP operating income was $20.3mm (+54%) and diluted EPS was $0.75 (+54%); non-GAAP adjusted operating income was $16.9mm (+29%) and adjusted EPS was $0.62 (+27%). Adjusted gross margin was 70.8% (up 300 bps). Cash rose by $23.6mm sequentially to $343.1mm. Growth drivers: grafts +23%, shunts +18%, Artegraft +33% (international launch). Regional sales: EMEA +18%, Americas +10%, APAC +4%. The board declared a quarterly dividend of $0.20/share payable Dec. 4, 2025, and authorized a $75.0mm share repurchase program through Feb. 17, 2026. Guidance: FY 2025 mid‑sales of $248mm (+13%) and adjusted full‑year operating income mid of $63.7mm.
LeMaitre Vascular (NASDAQ:LMAT) will release its third quarter 2025 financial results on Thursday, November 6, 2025 after the market close. A conference call to discuss results, business highlights, and outlook is scheduled the same day at 5:00 PM EST. Investors can register for live dial‑in access and a PIN or listen via a live audio webcast and replay at the company's investor site.